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We investigated the effects of frequency of hemodialysis on
nutritional status by analyzing the data in the Frequent
Hemodialysis Network Trial. We compared changes in
albumin, body weight, and composition among 245 patients
randomized to six or three times per week in-center
hemodialysis (Daily Trial) and 87 patients randomized
to six times per week nocturnal or three times per week
conventional hemodialysis, performed largely at home
(Nocturnal Trial). In the Daily Trial, there were no significant
differences between groups in changes in serum albumin or
the equilibrated protein catabolic rate by 12 months. There
was a significant relative decrease in predialysis body weight
of 1.5±0.2 kg in the six times per week group at 1 month,
but this significantly rebounded by 1.3±0.5 kg over the
remaining 11 months. Extracellular water (ECW) decreased in
the six times per week compared with the three per week
hemodialysis group. There were no significant between-
group differences in phase angle, intracellular water, or body
cell mass (BCM). In the Nocturnal Trial, there were no
significant between-group differences in any study
parameter. Any gain in ‘dry’ body weight corresponded
to increased adiposity rather than muscle mass but was
not statistically significant. Thus, frequent in-center
hemodialysis reduced ECW but did not increase serum
albumin or BCM while frequent nocturnal hemodialysis
yielded no net effect on parameters of nutritional status
or body composition.
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Chronic kidney disease is often accompanied by reductions
in serum albumin and prealbumin, and progressive loss
of muscle and adipose tissue, likely due to inadequate
macronutrient intake, inflammation,1 metabolic acidosis,2,3
reduced physical activity,4 or a combination of these
processes.5–7 Protein-energy wasting generally tends to
progress slowly once dialysis is initiated.8,9 Although several
putative causal factors may be corrected by better control of
uremia, the Mortality and Morbidity in Hemodialysis
(HEMO) Study showed no associations between increased
dialysis dose administered three times weekly and bio-
chemical proxies of protein-energy wasting assessed by
caliper anthropometry.10 Frequent (‘daily’) hemodialysis has
been reported to preserve nutritional status.11–13 Previous
studies of frequent hemodialysis were not randomized,
typically had small sample sizes, and used anthropometric
measures of body composition.
The Frequent Hemodialysis Network (FHN) Trials
aimed to examine the effects of increased hemodialysis
frequency on multiple intermediate outcome measures,
including nutritional status and body composition. Frequent
(six times per week) hemodialysis provided as in-center
daily or nocturnal at-home hemodialysis was compared
with conventional three times weekly hemodialysis. The
objectives and protocol summaries of both trials have been
previously published.14 Limited by sample size, the FHN
Trials were not designed to assess mortality or major health
events.
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We have previously reported that in-center and nocturnal
frequent hemodialysis interventions failed to increase the
12-month serum albumin concentration, which we stipulated
as the primary outcome for the nutritional status domain. In
this manuscript, we present treatment effects on equilibrated
protein catabolic rate (ePCR), a proxy for dietary protein
intake, and body composition, as reflected by bioimpedance-
measured resistance, reactance, phase angle, and vector
length, as well as derived estimates of intracellular (ICW)
and extracellular water (ECW) and body cell mass (BCM).
RESULTS
A total of 245 subjects were randomized in the Daily Trial,
and 87 subjects were randomized in the Nocturnal Trial.
Baseline characteristics are summarized in Table 1. Subjects
participating in both trials were diverse in terms of age, sex,
race/ethnicity, and other clinical characteristics. Although the
two trials were not formally compared, end-stage renal
disease vintage was shorter and residual kidney function
higher in the Nocturnal Trial. Although we had planned to
evaluate the effects of frequent hemodialysis on multiple
aspects of nutritional status and body composition, our
primary outcome within the nutrition domain was the
change in serum albumin concentration from baseline to end
of treatment (12 months). There were significant treatment
differences in weekly standard Kt/Vurea, and per-session and
weekly ultrafiltration volume, as previously reported.15,16
Serum albumin concentration
In the Daily Trial, predialysis serum albumin increased
1 month after randomization in the frequent compared
with conventional (3 /week) group (relative difference
0.06 g/dl, 95% confidence interval (0.01 to þ 0.13 g/dl)).
This difference was statistically significant over months 3–5
but was not sustained at 12 months. The change in albumin
from baseline to 12 months did not differ significantly
between treatment arms in either trial (Table 2, Figure 1a
and b). On the basis of a regression of serum albumin on the
preceding interdialytic interval, we estimated that the shorter
average interdialytic interval in the six times vs. the three
times per week group contributed 0.057±0.013 g/dl to the
treatment difference in serum albumin concentrations. Once
this sampling bias was accounted for, the changes in serum
albumin did not differ significantly between the treatment
groups at any follow-up time. In the Nocturnal Trial, there
were no significant between-group differences at any time,
although in both groups combined serum albumin increased
by 0.19±0.04 g/dl (Po0.001; Table 2, Figure 1b).
Equilibrated protein catabolic rate
For both the Daily and Nocturnal Trials, there were no
significant differences in ePCR between the treatment groups
at 1, 4, or 12 months (Figure 1c and d). In the Nocturnal
Trial, mean ePCR increased by 9.1±2.6 g/day from base-
line to 12 months in both treatment groups combined
(Figure 1d). The increases in serum albumin and ePCR
persisted and remained statistically significant compared with
baseline when the Nocturnal Trial analysis was restricted to
patients with baseline glomerular filtration rateo1.70ml/min,
the median baseline glomerular filtration rate.
Body weight
In the Daily Trial, there was a significant relative decrease
(frequent vs. conventional) in predialysis body weight evident
within 1 month (Figure 2a). Between 1 and 12 months, the
relative change in predialysis body weight was 1.3±0.5 kg
(P¼ 0.007) higher in the 6 times per week group. Postdialysis
body weight changed in parallel in both treatment groups
(Figure 2b). Between 1 and 12 months, the relative change in
postdialysis body weight was 1.1±0.5 kg (P¼ 0.04) higher in
the 6 times per week group.
In the Nocturnal Trial (Table 2, Figures 2c and d), pre-
and postdialysis weights in both treatment groups combined
decreased by 1 month after baseline, reaching a nadir at
2 months, with a slow increase toward and then beyond
baseline by 12 months, but with no significant difference
between treatment groups.
Measured parameters: reactance, resistance, phase angle,
and vector length
In the Daily Trial, there were statistically significant relative
increases in measured reactance and resistance in the 6 times
per week group at months 4 and 12. The vector length was
relatively lengthened in the 6 times per week group, reflecting
reduced tissue hydration (Table 2).
In the Nocturnal Trial, none of the between-group
comparisons reached statistical significance, with the exception
of vector length at 4 months, where the vector length was
significantly lengthened in the 6 times per week group (Table 2).
Derived estimates of body composition
In the Daily Trial, there were large relative decreases (frequent
vs. conventional) in total body water (TBW) evident at
1 month, which remained statistically significant at 4 and
12 months (Table 2, Figure 3a). The relative reduction
in TBW was confirmed using an independent determination
of the urea distribution volume from monthly urea kinetic
modeling (Table 2, Figure 3b). Changes in estimates of ECW
mirrored those of TBW (Figure 3c), suggesting that the
relative decline in TBW was driven by a change in ECW,
an observation consistent with the changes in vector length
described above. There were no significant relative changes
in ICW (Table 2, Figure 3d). Relative changes in TBW, ECW,
and ICWduring the Nocturnal Trial were small in magnitude
and not statistically significant (Table 2, Figure 4).
There was a relative increase in estimated adiposity in the
6 times per week group, although these changes did not
reach statistical significance in either trial (Table 2, Figures 5a
and c). Similarly, there were no statistically significant relative
changes in ICWor BCM, the metabolically active component
of lean body mass (Table 2, Figures 5b and d). Indeed, the
relative decrease in lean body mass could be explained
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virtually entirely by the relative decrease in ECW. There was no
evidence of enhanced ICWor BCM to reflect either anabolism
or preservation of BCM (Table 2, Figure 5b and d).
DISCUSSION
Frequent hemodialysis has been reported to preserve
nutritional status and prevent or attenuate the anticipated
decline in BCM,11,12,17 and has been associated with improved
appetite, increased protein and caloric intake, and incre-
mental increases in dry weight, muscle mass, and serum
albumin in various studies.11,12,17,18 In contrast to most pre-
vious studies, the FHN Daily and Nocturnal Trials were
randomized and used monthly measures of serum albumin,
ePCR, as well as serial bioimpedance-based measures, rather
than anthropometric measures of body composition.14,17 The
HEMO Trial, a 2 2 factorial randomized trial of 41800
Table 1 | Subject characteristics during baseline
Daily Trial Nocturnal Trial
Variables N
All
(N=245)
Three times
(N=120)
Six times
(N=125) N
All
(N=87)
Three times
(N=42)
Six times
(N=45)
Age (years) 245 50.4±13.9 52.0±14.1 48.9±13.6 87 52.8±13.6 54.0±12.9 51.7±14.4
Male 245 151 (61.6%) 73 (60.8%) 78 (62.4%) 87 57 (65.5%) 28 (66.7%) 29 (64.4%)
Race/ethnicity 245 87
White/Caucasian, non-Hispanic 89 (36.3%) 46 (38.3%) 43 (34.4%) 48 (55.2%) 21 (50.0%) 27 (60.0%)
Black/African–American/African 102 (41.6%) 53 (44.2%) 49 (39.2%) 23 (26.4%) 11 (26.2%) 12 (26.7%)
Hispanic and non-Black 69 (28.2%) 31 (25.8%) 38 (30.4%) 0 (0%) 0 (0%) 0 (0%)
Asian 16 (6.5%) 5 (4.2%) 11 (8.8%) 12 (13.8%) 7 (16.7%) 5 (11.1%)
Other/unknown 22 (9.0%) 8 (6.7%) 14 (11.2%) 1 (1.1%) 1 (2.4%) 0 (0%)
ESRD vintage (years) 245 87
o1 year (%) 40 (16.3%) 20 (16.7%) 20 (16.0%) 45 (51.7%) 25 (59.5%) 20 (44.4%)
1–o2 years (%) 32 (13.15) 15 (12.5%) 17 (13.6%) 13 (14.9%) 5 (11.9%) 8 (17.8%)
2–5 years (%) 76 (31.0%) 42 (35.0%) 34 (27.2%) 13 (14.9%) 5 (11.9%) 8 (17.8%)
45 years (%) 97 (39.6%) 43 (35.8%) 54 (43.2%) 16 (18.4%) 7 (16.7%) 9 (20.0%)
Diabetes 245 100 (40.8%) 50 (41.7%) 50 (40.0%) 87 37 (42.5%) 18 (42.9%) 19 (42.2%)
Congestive heart failure 245 49 (20.0%) 24 (20.0%) 25 (20.0%) 87 12 (13.8%) 7 (16.7%) 5 (11.1%)
Peripheral arterial disease 245 25 (10.2%) 10 (8.33%) 15 (12.0%) 87 15 (17.2%) 7 (16.7%) 8 (17.8%)
Stroke 245 18 (7.3%) 9 (7.5%) 9 (7.2%) 87 2 (2.3%) 1 (2.4%) 1 (2.2%)
Average weekly enPCR (g/kg/day) 245 1.02±0.25 1.03±0.25 1.02±0.25 84 0.99±0.25 0.99±0.23 0.98±0.28
PCR 245 63.4±20.0 63.4±19.1 63.5±20.9 84 63.6±21.3 64.4±22.4 62.8±20.3
Residual kidney function (ml/min) 245 87
=0 162 (66.1%) 72 (60.0%) 90 (72%) 24 (27.6%) 11 (26.2%) 13 (28.9%)
0–1 37 (15.1%) 19 (15.8%) 18 (14.4%) 16 (18.4%) 9 (21.4%) 7 (15.6%)
1–3 42 (17.1%) 27 (22.5%) 15 (12.0%) 28 (32.2%) 14 (33.3%) 14 (31.1%)
43 4 (1.6%) 2 (1.7%) 2 (1.6%) 19 (21.8%) 8 (19.0%) 11 (24.4%)
Creatinine (mg/dl) 245 10.54±2.72 10.32±2.45 10.76±2.95 87 8.74±2.99 8.89±3.06 8.59±2.94
Phosphate (mg/dl) 245 5.78±1.64 5.64±1.53 5.91±1.73 87 5.80±1.61 5.77±1.65 5.82±1.59
Hemoglobin (g/dl) 244 11.9±1.3 12.0±1.2 11.9±1.3 87 11.8±1.1 11.9±1.1 11.6±1.1
PTH (pg/ml=ng/l) 244 312 (69, 901) 287 (52, 873) 334 (89, 984) 87 322 (77, 635) 340 (112, 618) 296 (77, 640)
Albumin (g/dl) 245 3.94±0.42 3.94±0.46 3.94±0.37 87 3.91±0.49 3.92±0.51 3.90±0.48
Calcium (mg/dl) 245 9.01±0.92 9.04±0.96 8.99±0.89 87 8.83±0.80 8.96±0.79 8.71±0.80
Bicarbonate (mmol/l) 245 23.7±3.7 23.7±4.0 23.7±3.4 87 22.9±3.8 22.8±3.6 22.9±4.0
BMI (kg/m2) 245 27.6±6.7 27.6±6.8 27.5±6.6 87 29.1±7.9 28.4±7.6 29.8±8.3
Phase angle (degrees) 234 5.43±1.51 5.21±1.21 5.65±1.74 78 5.51±1.48 5.54±1.48 5.49±1.51
Intracellular water (l)/weight (kg) 234 0.267±0.062 0.261±0.061 0.273±0.062 78 0.268±0.066 0.273±0.065 0.264±0.068
Postdialysis weight (kg) 245 78.2±20.5 78.7±20.5 77.7±20.7 87 85.5±25.4 83.3±23.8 87.6±27.0
Adiposity (kg) 234 36.9±13.7 37.6±13.7 36.3±13.8 80 39.4±16.2 37.9±14.6 40.9±17.7
TBW 234 44.2±9.9 43.9± 10.2 44.5±9.7 78 47.3±11.8 46.7±11.4 47.9±12.2
ECW 234 22.8±4.5 22.9±4.7 22.7±4.4 78 24.2±5.9 23.8±5.6 24.6±6.2
ECW/ICW 234 1.13±0.31 1.16±0.30 1.12±0.32 78 1.12±0.32 1.11±0.32 1.13±0.33
Resistance (ohms) 234 474±95 488±99 460±89 80 468±100 470±90 467±111
Reactance (ohms) 234 48.5±13.3 48.2±13.6 49.0±14.1 78 48.1±13.5 48.7±13.3 47.5±13.8
Phase angle (degrees) 234 5.43±1.51 5.21±1.21 5.65±1.74 78 5.51±1.48 5.54±1.48 5.49±1.51
Vector length (ohms/m) 234 284.9±62.9 291.8±64.2 278.0±61.1 78 273.4±61.7 274.5±57.3 272.3±66.3
Abbreviations: BMI, body mass index; ECW, extracellular water; enPCR, equilibrated normalized protein catabolic rate; ESRD, end-stage renal disease; ICW, intracellular water;
PCR, protein catabolic rate; PTH, parathyroid hormone; TBW, total body water.
Results are shown as mean±s.d., median and 10th & 90th percentiles range, or frequency (%), as appropriate.
There were no significant differences between the treatment groups in each of the separate trials (Daily and Nocturnal) at baseline.
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Table 2 | Effects of treatment on nutrition and body composition
Observed data
(mean±s.d.)a
Adjusted means and treatment effectsb
(±s.e. or with 95% confidence intervals)
Month 4 Month 12
Variable Trial Treatment Baseline F4 F12
Change from
baseline
Treatment comparison
(6 vs. 3 )
Change from
baseline
Treatment comparison
(6 vs. 3 )
Serum albumin (g/dl)c Daily 3 3.95±0.44 3.94±0.4 3.96±0.4 0.02±0.03 0.08 (0.01, 0.14) P=0.016 0.00±0.03 0.03 (0.04, 0.10) P=0.41
6 3.96±0.36 4.0±0.37 3.98±0.36 0.06±0.03 0.03±0.03
Noct. 3 3.93±0.53 4.1±0.45 4.12±0.39 0.17±0.05 0.03 (0.10, 0.16) P=0.65 0.20±0.05 0.01 (0.14, 0.12) P=0.88
6 3.88±0.49 4.1±0.49 4.08±0.53 0.2±0.05 0.19±0.05
ePCR (g/day)c Daily 3 64.67±17.86 65.09±19.09 64.26±20.02 0.03±1.19 2.87 (0.27, 6.01) P=0.07 0.35±1.29 0.82 (2.54, 4.19) P=0.63
65.37±21.23 67.83±22.46 65.13±22.53 2.90±1.15 0.47±1.21
Noct. 6 62.42±21.6 63.28±21.49 69.97±24.23 1.65±3.24 5.76 (2.42, 13.94) P=0.17 6.3±3.33 5.65 (2.98, 14.27) P=0.20
62.86±21.15 70.96±22.05 74.55±38.81 7.41±3.24 11.94±3.45
Predialysis weight (kg)c Daily 3 81.75±20.26 81.89±20.5 81.97±20.37 0.25±0.27 1.29 (2.03, 0.56) P=0.001 0.15±0.38 0.21 (1.24, 0.82) P=0.69
6 80.17±21.26 79.25±21.49 80.28±21.51 1.05±0.26 0.06±0.36
Noct. 3 85.83±25.05 85.73±25.71 86.57±26.25 0.36±0.49 0.44 (1.79, 0.91) P=0.52 0.51±0.86 0.17 (2.2, 2.55) P=0.89
6 90.83±28.95 89.69±28.77 91.11±28.87 0.8±0.48 0.68±0.85
Postdialysis weight (kg)c Daily 3 78.9±19.76 79.1±19.9 79.19±19.86 0.37±0.28 0.45 (1.2, 0.3) P=0.24 0.23±0.45 0.62 (0.59, 1.83) P=0.32
6 77.01±20.84 77.07±21.18 78.15±21.2 0.08±0.27 0.85±0.43
Noct. 3 83.45±24.08 83.3±25.03 84.05±25.64 0.44±0.45 0.02 (1.25, 1.22) P=0.98 0.36±0.79 0.51 (1.66, 2.69) P=0.64
6 88.55±28.19 87.8±28.56 89.07±28.56 0.45±0.44 0.88±0.78
Reactance (ohms) Daily 3 48.2±12.6 47.8±15.1 47.4±15.2 0.6±1.2 5.7 (2.5, 8.9) Po0.001 0.9±1.5 5.2 (1.3, 9.2) P=0.010
6 48.9±14.1 54.5±14.3 53.3±15.3 5.1±1.2 +4.3±1.4
Noct. 3 48.7±13.3 51.4±15.1 53.9±13.9 2.6±2.6 3.4 (3.4, 10.2) P=0.32 +4.5±2.5 1.4 (5.1, 7.9) P=0.67
6 47.5±13.8 54.3±16.9 53.9±16.2 6.0±2.6 +5.8±2.5
Daily 3 488±99 471±92 466±91 11.0±5.8 +36.9 (21.8, 52.1) Po0.001 11.7±7.4 30.4 (11.1, 49.6) P=0.002
6 460±89 494±96 492±93 26.0±5.4 +18.7±7.0
Noct. 3 470±90 471±98 483±108 3.4±9.3 +30.8 (4.7, 57.0) P=0.021 +6.2±12.2 17.9 (16.5, 52.2) P=0.30
6 467±111 493±117 481±94 34.3±9.3 +24.1±12.5
Phase angle (degrees) Daily 3 5.21±1.21 5.32±1.44 5.34±1.58 0.01±0.13 +0.30 (0.03, 0.63) P=0.075 0.02±0.15 0.28 (0.11, 0.67) P=0.16
6 5.65±1.74 5.91±1.85 5.78±1.96 0.31±0.12 +0.25±0.14
Noct. 3 5.54±1.48 5.76±1.48 5.98±1.66 0.16±0.24 +0.09 (0.53, 0.72) P=0.77 +0.37±0.22 0.05 (0.66, 0.56) P=0.87
6 5.49±1.51 5.81±1.69 5.79±1.67 0.25±0.24 +0.32±0.23
Vector length (ohms/m) Daily 3 291.8±64.2 281.7±59.3 278.1±58.2 6.9±3.5 +23.4*** (14.1, 32.7) Po0.001 7.5±4.6 19.6** (7.6, 31.6) P=0.0015
6 278.0±61.1 298.8±66.8 297.4±65.2 16.5±3.3 +12.1±4.3
Noct. 3 274.5±57.3 279.9±67.3 289.4±75.1 4.1±5.7 17.5* (1.4, 33.5) P=0.033 +6.0±7.5 9.4 (11.6, 30.5) P=0.38
6 460.5±95.4 496.7±117.5 484.2±93.5 35.6±9.7 +25.2±12.7
Total body water (l) Daily 3 43.9±10.2 44.1±9.7 44.9±9.6 0.5±0.3 1.7 (2.4, 1.0) Po0.001 +0.6±0.3 1.3 (2.1, 0.4) P=0.004
6 44.5±9.7 43.0±9.9 43.1±10.2 1.2±0.2 0.7±0.3
Noct. 3 46.7±11.4 45.9±11.4 44.7±11.3 0.3±0.4 1.1 (2.3, 0.1) P=0.065 0.1±0.6 0.4 (2.2, 1.3) P=0.63
6 47.9±12.2 47.1±12.2 48.1±11.9 1.4±0.4 0.5±0.6
Kinetic volume (l)c Daily 3 36.2±8.6 37.2±9.3 37.1±8.5 0.62±0.45 1.96 (3.14, 0.78) P=0.001 0.31±0.48 1.55 (2.8, 0.29) P=0.02
6 36.8±9.5 35.6±8.5 35.6±9.1 1.34±0.43 1.24±0.45
Noct. 3 38.2±12.1 39.6±13.6 38.7±13.5 1.32±1.44 2.53 (6.21, 1.14) P=0.18 0.97±1.47 0.56 (4.38, 3.26) P=0.77
6 37.6±9.3 36.5±11.0 41.2±20.5 1.22±1.43 0.42±1.51
Extracellular water (l) Daily 3 22.9±4.7 23.1±4.7 23.4±4.9 0.26±0.23 1.26 (1.87, 0.65) Po0.001 +0.44±0.26 1.12 (1.83, 0.41) P=0.002
6 22.7±4.4 21.4±4.3 21.6±4.4 1.00±0.22 0.68±0.25
Noct. 3 23.8±5.6 23.2±5.9 22.3±5.4 0.38±0.48 0.76 (2.09, 0.58) P=0.26 0.68±0.45 0.02 (1.23, 1.27) P=0.98
6 24.6±6.2 23.7±6.3 24.3±5.9 1.13±0.48 0.66±0.46
Intracellular water (l) Daily 3 21.0±6.5 21.1±6.4 21.6±6.1 0.27±0.20 0.46 (0.99, 0.08) P=0.094 +0.13±0.23 0.19 (0.81, 0.44) P=0.562
6 21.9±6.9 21.6±7.0 21.5±7.4 0.19±0.19 0.05±0.22
Noct. 3 22.8±7.3 22.8±6.8 22.4±7.5 0.02±0.33 0.12 (1.04, 0.80) P=0.80 +0.53±0.43 0.22 (1.45, 1.01) P=0.73
6 23.3±7.6 23.4±7.4 23.8±7.5 0.14±0.33 +0.31±0.44
Body cell mass (kg) Daily 3 26.6±8.2 26.7±8.0 27.3±7.7 0.34±0.25 0.58 (1.26, 0.10) P=0.094 +0.17±0.30 0.23 (1.03, 0.56) P=0.56
6 27.7±8.8 27.3±8.8 27.3±9.3 0.24±0.24 0.07±0.28
Noct. 3 28.9±9.2 28.8±8.6 28.4±9.5 0.02±0.41 0.15 (1.31, 1.01) P=0.80 +0.67±0.55 0.28 (1.84, 1.28) P=0.73
6 29.5±9.6 29.7±9.4 30.2±9.5 0.17±0.41 +0.39±0.56
Lean body mass (kg) Daily 3 44.0±10.2 44.2±9.7 45.0±9.6 0.53±0.26 1.68 (2.37, 0.99) Po0.001 +0.58±0.32 1.26 (2.12, 0.41) P=0.004
6 44.6±9.8 43.1±9.9 43.2±10.3 1.15±0.24 0.68±0.30
Noct. 3 46.3±11.7 46.1±11.5 44.8±11.4 0.23±0.41 1.11 (2.25, 0.04) P=0.057 0.04±0.61 0.45 (2.18, 1.28) P=0.61
6 47.4±12.5 47.2±12.2 48.2±12.0 1.34±0.41 0.49±0.63
% Adiposity Daily 3 37.6±13.7 36.8±13.4 37.3±12.8 0.23±0.29 +0.40 (0.38, 1.18) P=0.31 0.09±0.41 0.76 (0.34, 1.85) P=0.17
6 36.3±13.8 36.2±13.5 35.5±12.9 0.18±0.27 +0.67±0.38
Noct. 3 37.9±14.6 37.7±14.5 37.5±15.1 0.53±0.57 +0.78 (0.78, 2.35) P=0.32 0.17±0.81 1.90 (0.36, 4.17) P=0.10
6 40.9±17.7 42.5±18.1 44.4±18.5 0.25±0.56 +1.73±0.82
Abbreviations: ePCR, equilibrated protein catabolic rate; Noct., Nocturnal.
aMeans and s.d.’s are provided for constant cohorts with non-missing values at each of the baseline, month 4, and month 12 visits. Sample sizes ranges from 77 to
116 (3 per week) and 89 to 123 (6 per week) in the Daily Trial, and from 35 to 42 (3 per week) and 33 to 44 (6 per week) in the Nocturnal Trial.
bAdjusted means and treatment effects were estimated under mixed-effects models with adjustment for the baseline level of the outcome and clinical center in the Daily
Trial, and the baseline level of the outcome in the Nocturnal Trial.
cMonth 4 and month 12 designate averages over months 3–5 and months 10-12, respectively, for outcomes measured at monthly kinetic modeling sessions.
*P¼o0.05, **P¼o0.01, ***P¼o0.001.
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subjects dialyzed three times per week at standard and high
per session eKt/Vurea and with high and low flux dialyzers,
showed a progressive decline in serum albumin, equilibrated
normalized protein catabolic rate, and body weight10
unaffected by dialysis dose or flux. No significant effect on
weight was observed during the first year of HEMO, but over
time there were decreases in both estimated muscle and fat
mass in all groups.19
The FHN Trials showed no statistically significant
between-group differences in serum albumin from baseline
to 12 months. Although serum albumin concentrations have
been reported to increase during the first year of dialysis,20
possibly related to a reduction in proteinuria or improved
nutritional status, the observed increases in serum albumin in
both arms of the Nocturnal Trial were not associated with
residual kidney function or proximity to the initiation of
dialysis therapy (data not shown).
Body weight is an imprecise nutritional marker in patients
on dialysis, as weight gain may reflect increases in ECW,
BCM (reported by an increase in ICW), and/or fat mass.
A biphasic pattern of change in body weight has previously
been described after switching from three times to six times
per week dialysis.21 Presumably, the initial drop is due to
a reduction in ECW, and subsequent weight gain results
from improved appetite and increased tissue weight. In the
Daily Trial, the monthly predialysis body weights in subjects
randomized to the six times per week group followed such
a pattern. Bioelectrical impedance analysis (BIA)-derived
data at 1 month confirmed a reduction in TBW and
ECW with no significant change in ICW. At 12 months, the
average predialysis body weight had returned to baseline
levels, whereas the reduction in ECW persisted. There was no
evidence of a gain in ICW and, correspondingly, BCM. These
results suggest that the body weight gain was in a non-
hydrated body compartment, probably fat. Whether an increase
in adiposity in patients on hemodialysis is beneficial or
harmful is unknown; observational data suggest that higher
body mass index is associated with enhanced survival.22
We found no significant changes in ICW or phase angle
with frequent compared with conventional hemodialysis.
In an adult population, changes in ICW and phase angle
result predominantly from changes in muscle mass, as non-
muscle organ mass should remain relatively constant over
time. Acidosis,23,24 inflammation,25,26 and reduced physical
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activity, all common in the dialysis population, are associated
with decline in muscle mass, whereas increased resistive
training27 or androgen replacement may be associated with
increased muscle mass.28,29 Thus, the expected effect of
change in dialysis frequency might be one of protection from
loss rather than an increase in muscle mass. Our observations
suggest that factors responsible for the deterioration of
nutritional status seen in other studies was attenuated or
possibly prevented because of patient selection, ‘adequate’
hemodialysis in the three times per week group, or that the
period of observation was simply too short.
Our study is strengthened by data from two randomized
clinical trials involving a relatively large sample of subjects
reasonably representative of the North American hemodia-
lysis population. We also included monthly measures of
nutritional parameters, and used serial bioimpedance-based
measures of body composition. This study also has limita-
tions. We did not measure adiposity directly in this study.
Our estimation of change in adiposity and difference in
adiposity between the groups is based on subtraction of two
relatively large values, body weight and TBW, from one
another. Each is accompanied by a measurement error,
decreasing precision in our estimate of differences in body fat
mass between treatment groups. We used single-frequency
BIA rather than isotope dilution methodology to determine
body composition and calculated adiposity by assuming
hydration of fat-free mass (FFM) of 0.73. The relative
expansion of ECW found in patients on hemodialysis
might lead to an underestimation of the hydration of FFM.
Nevertheless, ECW/ICW varies greatly in humans as a
function of age, sex,30 and obesity,31 with no significant
change in the hydration of FFM measured directly.
In conclusion, frequent in-center hemodialysis signifi-
cantly reduced ECW but failed to anabolize (i.e., no increase
in serum albumin or BCM). Any gain in ‘dry’ body weight
corresponded to increased adiposity rather than muscle mass.
Frequent nocturnal hemodialysis yielded no net effect on
parameters of nutritional status or body composition.
MATERIALS AND METHODS
Study design
The FHN Daily Trial was a multicenter, prospective, randomized
trial of frequent (six times per week), as compared with conven-
tional (three times per week), in-center hemodialysis. The FHN
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Nocturnal Trial was a multicenter, prospective, randomized trial of
frequent (six times per week) nocturnal at-home hemodialysis, as
compared with conventional hemodialysis (three times per week),
with the majority of conventional subjects receiving home-based
therapy. The study designs, including specific inclusion and
exclusion criteria, and data collection procedures have been
described previously.14
Study population
Subjects with end-stage renal disease requiring maintenance
hemodialysis who achieved a mean eKt/Vurea 41.0 for the last
two baseline dialysis sessions and weighed 430 kg were eligible for
inclusion. Major exclusion criteria included age o13 (Daily) or o18
(Nocturnal) years, residual kidney function43ml/min/35 l (Daily),
or mean of creatinine and urea clearance 410ml/min/1.73m2
(Nocturnal). Informed consent was obtained from each subject.
The study was approved by the Institutional Review Board at each
participating study site.
Intervention, control, and adherence
In the Daily Trial, subjects who were assigned to hemodialysis six
times per week (n¼ 125) had a target equilibrated Kt/Vn (where
Vn¼ 3.271V2/3) of 0.9, provided that each session length was
between 1.5 and 2.75 h. Subjects who were assigned to three
times per week hemodialysis (n¼ 120) continued their usual
dialysis prescriptions, which included a minimum target equili-
brated Kt/Vurea (the ratio of the equilibrated urea clearance during
each dialysis session (Kt) to the patient’s volume of urea distribution
(V)) of 1.1 and a session length of 2.5 to 4.0 h.
In the Nocturnal Trial, subjects were assigned to dialysis either
3 times per week (n¼ 42) to a prescribed standardized Kt/Vurea of
42.0/week and a session length of X2.5 h or 6 times per week
(n¼ 45) to a standardized Kt/Vurea of X4.0/week and a session
length ofX6 h. For both trials, we calculated adherence as the ratio
of dialysis sessions attended to dialysis sessions prescribed, by
month.
Outcome measures
The prespecified primary outcome for the ‘nutrition domain’ was
serum albumin concentration, measured monthly throughout the
follow-up period. Additional outcomes with monthly measurements
included pre- and postdialysis weight, urea kinetic volume (V), and
protein catabolic rate (ePCR) calculated using the equilibrated
postdialysis blood urea nitrogen. We analyzed absolute ePCR in
g/day without normalizing to V, to avoid confounding with
projected changes in V.
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Body composition was assessed by single-frequency (50 kHz;
Quantum, RJL Systems, Clinton Township, MI) BIA at baseline, 1
month, 4 months, and 12 months in the Daily Trial, and at baseline,
4 months, and 12 months in the Nocturnal Trial. The protocol
instructed clinical centers to implement the BIA procedure before a
mid-week hemodialysis session for subjects with at least one intact
leg and arm when feasible; however, a minority of BIA assessments
were performed on other days or after dialysis. We measured
reactance (Xc) and resistance (R), and calculated phase angle, the arc
tangent of the Xc-to-R ratio. We multiplied the arc tangent of Xc/R
by 180/p to convert from radians to degrees. We used reactance to
estimate total body potassium (TBK) by the method of Kotler
et al.32 We estimated BCM using the following equation:
BCM (kg)¼ 0.00833TBK (mmol).33
ICW was then calculated as 0.73BCM.34
We estimated adiposity (fat mass) by subtracting FFM (estimated
as TBW/0.73) from total (postdialysis) body weight.
Statistical analysis
Continuous variables were summarized using means and s.d.’s, and
categorical variables were summarized using frequencies and
proportions. Descriptive summaries of changes in treatment-related
variables are provided for the constant cohort with non-missing
values at baseline and at months 4 and 12 after randomization.
The effects of randomized treatment assignment on outcomes
with monthly measurements (predialysis serum albumin, ePCR,
pre- and postdialysis weight, and kinetic volume) were estimated
using mixed-effects analyses, with covariate adjustment for the
baseline level of the outcome and clinical center in the Daily Trial,
and the baseline level of the outcome in the Nocturnal Trial. We
used a combined compound symmetry first-order auto-regressive
covariance matrix to account for correlations in measurements over
time.35 A heteroscedastic extension of the covariance model was
used for the pre- and postdialysis weights in the Daily Trial to
account for a greater variability in weight at baseline than during
follow-up. The analytic approach accounted for non-missing early
measurements in the analysis of changes to later time points in cases
for subjects who died or dropped out of the study during the follow-
up period. Treatment effects were assessed primarily by comparisons
between randomized groups of adjusted mean changes from
baseline to the average level during months 10–12. Additional
comparisons between randomized groups were defined for the mean
changes from baseline to the average level during months 3–5, and
for the mean changes from months 3–5 to the average level during
months 10–12, to separately assess the effects of the treatment
interventions on early and later changes. In accordance with the
study design, primary emphasis was given to comparisons between
treatment groups; however, further contrasts were defined to
estimate mean changes over each of these time intervals (baseline
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to months 10–12, baseline to months 3–5, and months 3–5 to
months 10–12) within each randomized group and for the average of
the two groups combined. Finally, the same mixed-effects models
were used to provide adjusted mean changes from baseline to each
follow-up month for plots representing the pattern of change over
the entire 1-year follow-up period.
Similar mixed-effects models were used to estimate treatment
effects on changes in BIA measurements; only in this case, an
unstructured covariance model was used to account for serial
correlation in repeated measurements within the same patients
(baseline and months 1, 4, and 12 in the Daily Trial; baseline and
months 4 and 12 in the Nocturnal Trial). Analogous to monthly
outcomes, we focused primarily on comparisons of changes to the
end of follow-up (month 12), but also evaluated treatment effects on
changes from baseline to month 4 and from month 4 to month 12.
The mixed-effects models for TBW and intracellular body water
were extended in both trials by adding linear interaction terms to
investigate whether the treatment effects differed among subjects
with lower and higher levels of the prespecified baseline factors, age
and BMI.
In sensitivity analyses, the mixed-effects analyses for the
monthly outcomes were repeated for the Nocturnal Trial after
excluding patients with baseline residual renal clearance (defined as
the average of urea and creatinine clearance) o1.70ml/min, the
median baseline value for the Nocturnal Trial. We estimated the
effect of hemodilution associated with the interdialytic interval
on the predialysis serum albumin concentrations by extending
the mixed-effects models in each trial to relate the predialysis
albumin to the inter-dialytic interval preceding the blood draw after
controlling for clinical center (Daily Trial only) and treatment
assignment, the interaction between treatment assignment and
visit month, diabetes, age, baseline glomerular filtration rate, and
clinical center (both trials). We then applied the estimated regression
coefficients from these models to the mean interdialytic intervals in
the respective treatment groups to assess the influence of different
average interval lengths on comparisons of serum albumin between
the six times per week and three times per week treatment groups.
All analyses were performed without formal adjustment for multiple
comparisons using SAS version 9.2 (Cary, NC). Two-tailed P-values
o0.05 were considered statistically significant.
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